Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
5.
Cytometry B Clin Cytom ; 90(1): 54-60, 2016 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-26147493

RESUMO

People with myeloma who obtain a good response to treatment have a better survival if sensitive molecular or flow-cytometric techniques show no detectable minimal residual disease (MRD). The application of MRD techniques to clinical trials is now considered to be increasingly important because treatment approaches are sufficiently effective that using survival outcomes is slowing down the identification of the best new treatments. The articles in this issue consider the laboratory requirements for harmonization of MRD analysis by flow cytometry but there are practical considerations that are also important in implementing a myeloma MRD assay in the cytometry laboratory. In particular, it is important to consider when to request, and how best to utilize, a bone marrow aspirate sample because the procedure is invasive and the cells obtained are valuable for a number of different investigations. This brief article considers some experience obtained over two decades of implementing a service for MRD detection, initially as a scientific bolt-on to clinical trials through to a routine clinical diagnostic assay.


Assuntos
Antígenos CD/análise , Serviços de Laboratório Clínico/história , Citometria de Fluxo/normas , Mieloma Múltiplo/diagnóstico , Neoplasia Residual/diagnóstico , Antígenos CD/genética , Antígenos CD/imunologia , Antineoplásicos/uso terapêutico , Biópsia por Agulha , Células da Medula Óssea/efeitos dos fármacos , Células da Medula Óssea/patologia , Expressão Gênica , História do Século XX , História do Século XXI , Humanos , Cadeias Pesadas de Imunoglobulinas/genética , Cadeias Pesadas de Imunoglobulinas/imunologia , Mieloma Múltiplo/mortalidade , Mieloma Múltiplo/patologia , Mieloma Múltiplo/terapia , Neoplasia Residual/mortalidade , Neoplasia Residual/patologia , Neoplasia Residual/terapia , Plasmócitos/efeitos dos fármacos , Plasmócitos/patologia , Prognóstico , Indução de Remissão , Análise de Sobrevida , Reino Unido
6.
Rev. cuba. hematol. inmunol. hemoter ; 35(2): e961, abr.-jun. 2019. graf
Artigo em Espanhol | LILACS, CUMED | ID: biblio-1093264

RESUMO

Los doctores Moisés y Alejandro Chediak Ahuayda, cubanos de ascendencia libanesa, realizaron importantes contribuciones a la Inmunología y otras ciencias médicas. El doctor Moisés Chediak fue director del Laboratorio Clínico Central del Hospital General Calixto García desde 1940, año en que fundó el primer banco de sangre de Cuba. Llegó a ser Profesor Auxiliar de Microscopía y Química Clínica de la Universidad de la Habana. Entre sus artículos se destacan el primer caso de anemia de Cooley en un niño en Cuba, así como el reporte de una nueva forma de inmunodeficiencia primaria conocida como síndrome de Béguez-Chediak-Higashi. Participó en numerosos eventos en América, Europa y Asia, y fue un miembro reconocido de las Sociedades Cubanas de Patología Clínica, Microbiología y de Pediatría, así como de organizaciones internacionales. Alejandro Chediak llamó la atención de la comunidad científica al desarrollar un método que solo requería de una gota de sangre en papel para el diagnóstico serológico de la sífilis. La microrreacción de Chediak fue ampliamente evaluada, adoptada y modificada en Estados Unidos, Argentina, Alemania, Polonia, México, Chile, Brasil y Francia. Diseñó un dispositivo útil para diversas técnicas de laboratorio, como la aglutinación de grupos sanguíneos, el cual fue patentado en Cuba y Estados Unidos. Fue profesor de Física Biológica de la Facultad de Medicina de la Universidad de La Habana. Los hermanos Chediak Ahuayda, quienes se formaron y alcanzaron sus más importantes resultados profesionales en nuestro país, ocupan un lugar destacado en la historia de la medicina cubana del siglo XX(AU)


Doctors Moises and Alejandro Chediak Ahuayda, whose were born in Cuba and had Lebanese ascendants, made important contributions to Immunology and other medical sciences. Doctor Moises Chediak was director of the Central Clinical Laboratory of the General Calixto Garcia Hospital from 1940, the same year when he founded the first blood bank in Cuba. He was Associate Professor of Microscopy and Clinical Chemistry at the University of Havana. The first report in Cuba of a case of Cooley's anemia in a child, and a new form of a primary immunodeficiency, known as Beguez-Chediak-Higashi syndrome, were among his most relevant papers. He participated in many congressesin America, Europe and Asia; he was an outstanding member of the Cuban Societies of Clinical Pathology, Microbiology and Pediatrics, as well as various international organizations. Alejandro Chediak got the attention of the scientific community when he developed a method that required only a drop of blood in a paper for the serological diagnostics of syphilis. Chediak's microrreaction was widely evaluated, adopted and modified in the United States, Argentina, Germany, Poland, Mexico, Chile, Brazil and France. He designed a device useful for many laboratory assays, including blood group agglutination, patented in Cuba and the United States. He was professor of Biological Physics at the Faculty of Medicineof theUniversity of Havana. The brothers Chediak Ahuayda, who were trained and obtained their most important professional achievements in our country, have a relevant place in the history of Cuban medicine during XX century(AU)


Assuntos
Humanos , Masculino , Personalidade , Serviços de Laboratório Clínico/história , Hematologia/história , Síndrome de Chediak-Higashi/história , Cuba , História da Medicina
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA